AFP and cirrhosis of liver: These findings might encourage the use of the aforementioned epigenetic ncRNA markers in panels or ratios as prospective blood-based molecular markers of benefit, during liver cirrhosis early identification and/or CHCV-G4 infection follow-up, for possible HCC development as well as for ensuring all AFP-negative HCC cases’ identification.